Advertisement
Kidney International
ISN
Advanced SearchSave search
Editorial: Special Report| Volume 98, ISSUE 1, P20-26, July 01, 2020

A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection

Published:May 10, 2020DOI:https://doi.org/10.1016/j.kint.2020.04.030
A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection
Previous ArticleCOVID-19 in dialysis patients: adding a few more pieces to the puzzle
Next ArticleCOVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain
      The SARS-CoV-2 epidemic is pressuring healthcare systems worldwide. Disease outcomes in certain subgroups of patients are still scarce, and data are needed. Therefore, we describe here the experience of four dialysis centers of the Brescia Renal COVID Task Force. During March 2020, within an overall population of 643 hemodialysis patients, SARS-CoV-2 RNA positivity was detected in 94 (15%). At disease diagnosis, 37 of the 94 (39%) patients (group 1) were managed on an outpatient basis, whereas the remaining 57 (61%) (group 2) required hospitalization. Choices regarding management strategy were made based on disease severity. In group 1, 41% received antivirals and 76% hydroxychloroquine. Eight percent died and 5% developed acute respiratory distress syndrome (ARDS). In group 2, 79% received antivirals and 77% hydroxychloroquine. Forty two percent died and 79% developed ARDS. Overall mortality rate for the entire cohort was 29%. History of ischemic cardiac disease, fever, older age (over age 70), and dyspnea at presentation were associated with the risk of developing ARDS, whereas fever, cough and a C-reactive protein higher than 50 mg/l at disease presentation were associated with the risk of death. Thus, in our population of hemodialysis patients with SARS-CoV-2 infection, we documented a wide range of disease severity. The risk of ARDS and death is significant for patients requiring hospital admission at disease diagnosis.

      Graphical abstract

      Figure thumbnail fx1
      Graphical Abstract

      Keywords

      The impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in subgroups of patients has yet to be determined. In Brescia, Italy, we have developed a standardized protocol when approaching patients on maintenance hemodialysis (MHD) and kidney transplant recipients, respectively.
      • Alberici F.
      • Delbarba E.
      • Manenti C.
      • et al.
      Management of patients on dialysis and with kidney transplantation during the SARS-CoV-2 (COVID-19) pandemic in Brescia, Italy.
      Kidney Int Rep. 2020; 5: 580-585
      Reports would suggest a more severe disease course in patients with chronic kidney disease,

      Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection [e-pub ahead of print]. Int Urol Nephrol. https://doi.org/10.1007/s11255-020-02451-9. Accessed April 13, 2020.

      although outcomes in MHD patients are still unclear, with earlier small case series suggesting a milder course.

      Wang R, Liao C, He H, et al. COVID-19 in hemodialysis patients: a report of 5 cases [e-pub ahead of print]. Am J Kidney Dis. https://doi.org/10.1053/j.ajkd.2020.03.009. Accessed April 12, 2020.

      Management of MHD patients in the context of an epidemic poses several challenges: this group of patients usually requires caregiver assistance and transportation from home to the dialysis units, and they must spend time in crowded waiting areas before and after treatment.
      • Burgner A.
      • Ikizler T.A.
      • Dwyer J.P.
      COVID-19 and the inpatient dialysis unit: managing resources during contingency planning pre-crisis.
      Clin J Am Soc Nephrol. 2020; 15: 720-722
      Moreover, MHD patients are usually old and affected by several comorbidities that are known to be associated with high risk of poor outcomes in patients with coronavirus disease 2019 (COVID-19).
      The Lombardy region in general, and Brescia in particular, have been severely hit by the SARS-CoV-2 epidemic, and this has generated several logistical and clinical challenges for the dialysis units of the Brescia Renal COVID Task Force. Here, we describe the characteristics and outcomes of the MHD patients affected by COVID-19 and followed in 4 dialysis units that are part of the Brescia Renal COVID Task Force.

       Results

      Ninety-four patients tested positive via reverse transcription polymerase chain reaction (RT-PCR) within the overall population of 643 (15%; Table 1). Although 3 centers limited the viral testing to only those patients showing symptoms suggestive for SARS-CoV-2 infection, the hemodialysis center of the ASST Spedali Civili of Brescia performed RT-PCR in its entire MHD population (patients with symptoms and patients without symptoms). The positivity rates were not substantially different between these approaches (14% vs. 16%, respectively). Patients testing positive were either triaged to the hospital or back to their dialysis facility based on the clinical judgement of the caring physician, mainly according to the severity of the symptoms shown. The main clinical characteristics of the overall MHD population with SARS-CoV-2 infection, and the subgroups managed as outpatient or in hospital, are shown in Table 2. The median time from symptom onset to positive RT-PCR was 2 days (interquartile range [IQR], 0–3). Patients that needed to be admitted showed a higher proportion of symptoms compared to the ones not requiring hospitalization (46% vs. 14%).
      Table 1Hemodialysis patients with SARS-CoV-2 infection in 4 dialysis centers of the Brescia Renal COVID Task Force, Brescia, Italy
      CenterPositive patients admittedPositive outpatientsPositive overallOverall populationPercentage of positive patients
      Brescia25224930216
      Chiari16143015519
      Manerbio120129912
      Montichiari415876
      TOTAL57379464315
      COVID, coronavirus disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
      Table 2Baseline clinical characteristics of 94 hemodialysis patients affected by SARS-CoV-2 infection and followed within 4 centers of the Brescia Renal COVID Task Force, Brescia, Italy
      CharacteristicsAll patients (94)Outpatients (37)Admitted (57)P value
      Comparison between the 2 groups—“outpatients” and “admitted.”
      Male/female62/3224/1339/180.82
      Age (yr)72 (62–79)67 (60–77)73 (64–80)0.17
      Cause of ESRD
       Not determined40 of 94 (43)8 of 37 (22)32 of 57 (56)0.001
       Glomerulonephritis19 of 94 (19)15 of 37 (41)4 of 57 (7)0.0001
       Genetic diseases15 of 94 (16)6 of 37 (16)9 of 57 (16)1
       Diabetes11 of 94 (12)3 of 37 (8)8 of 57 (14)0.52
       Other9 of 94 (10)5 of 37 (14)4 of 57 (7)0.31
      Comorbidities
       Hypertension93%35 of 7 (95)52 of 57 (91)0.7
       Diabetes43%13 of 37 (35)27 of 57 (47)0.29
       Vascular disease23%7 of 37 (19)15 of 57 (26)0.46
       Cardiac failure18%1 of 37 (3)16 of 57 (28)0.002
       Ischemic cardiac disease17%4 of 37 (11)12 of 57 (21)0.27
       Cancer12%5 of 37 (14)6 of 57 (11)0.75
       COPD11%6 of 37 (16)4 of 57 (7)0.18
       Other17%4 of 37 (11)13 of 57 (23)0.18
      Hemodialysis vintage (yr)3 (1–6)2 (1–7)3.9 (1.6–6.4)0.19
      Hemodialysis frequency
       2 times week12 of 94 (13)3 of 37 (8)9 of 57 (16)0.35
       3 times a week82 of 94 (87)34 of 37 (92)48 of 57 (84)0.35
      Hemodialysis modality
       HD69 of 94 (73)26 of 37 (70)43 of 57 (75)0.64
       HDF23 of 94 (25)11 of 37 (30)12 of 57 (21)0.46
       AFB2 of 94 (2)02 of 57 (4)0.52
      SARS-CoV-2 infection symptoms at disease onset
       Temperature (>37.5 °C)68%16 of 37 (43)49 of 57 (86)<0.0001
       Cough23%6 of 37 (16)16 of 57 (28)0.22
       Gastrointestinal symptoms6%1 of 37 (3)5 of 57 (9)0.4
       Pharyngitis2%1 of 37 (3)1 of 57 (2)1
       Shortness of breath25%1 of 37 (3)22 of 57 (39)<0.0001
       Myalgia17%2 of 37 (5)14 of 57 (25)0.02
      Baseline chest X-ray
       No infiltrates30%15 of 31 (48)11 of 53 (21)0.01
       Unilateral infiltrates25%7 of 31 (23)13 of 53 (25)1
       Bilateral infiltrates45%9 of 31 (29)29 of 53 (55)0.03
      Baseline blood tests
       WBC (NV 4.00–10.80 × 103/ul)5075 (3943–6470)5960 (4095–6865)4760 (3910–5645)0.08
       Neutrophils (NV 1.50–8.00 × 103/ul)3505 (2688–4770)4400 (2760–5330)3430 (2680–4080)0.1
       Lymphocytes (NV 0.90–4.00 × 103/ul)745 (550–1085)900 (600–1200)623 (510–1000)0.05
       Platelets (NV 130–400 × 103/ul)162,000 (126,000–229,500)202,000 (124,250–263,750)151,000 (127,000–181,000)0.02
       LDH (NV 135–225 U/l)254 (193–354)218 (187–303)352 (219–404)0.004
       CPK (NV 39–308 U/l)64 (38–138)51.5 (33–143)96 (49–138)0.33
       AST (NV 18–54 U/l)23 (17–35)19 (12–24)27 (19–46)0.0002
       ALT (NV 10–50 U/l)17 (11–25)14.5 (10–21)19 (13–29)0.04
       Bilirubin (NV < 1.20 mg/dl)0.3 (0.28–0.4)0.28 (0.21–0.37)0.3 (0.3–0.5)0.05
       CRP (NV < 5.0 mg/l)42.9 (10–82)12.8 (3.7–33.8)60 (19–89)0.0004
      Time from symptom onset to antiviral therapy initiation4 (1–6)5 (3–5)3 (1–6.5)0.05
      Time from RT-PCR positivity to antiviral therapy initiation2 (0–4)3 (2–5)1 (0–3)0.0003
      Antiviral therapy
       Lopinavir/ritonavir19 of 94 (20)0 of 37 (0)19 of 57 (33)
       Darunavir + ritonavir41 of 94 (44)15 of 37 (41)26 of 57 (46)
       Hydroxychloroquine72 of 94 (77)28 of 37 (76)44 of 57 (77)
      Data are reported as n (%) for categorical variables and median (interquartile range) for continuous variables. Bold data refer to statistically significant P values.
      AFB, acetate-free biofiltration; ALT, alanine aminotransferase; AST, aspartate aminotransferase; COPD, chronic obstructive pulmonary disorder; COVID, coronavirus; CPK, creatine phosphokinase; CRP, C-reactive protein; ESRD, end-stage renal disease; HD, hemodialysis, HDF, hemodiafiltration; LDH, lactate dehydrogenase; NV, normal values; RT-PCR, reverse transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WBC, white blood cell.
      a Comparison between the 2 groups—“outpatients” and “admitted.”

       Outpatient management

      Thirty-seven of 94 (39%) patients were managed as outpatients, for a median follow-up of 8 days (IQR, 6–11). Among the group managed as outpatients, 18 of 37 (49%) were asymptomatic at disease diagnosis, while the remaining patients experienced mild symptoms. Among the asymptomatic patients, in 13 of 18 (72%), a chest X-ray was negative, and unilateral and bilateral infiltrates were detected respectively in 3 of 18 (17%) and 2 of 18 (11%). Detailed patient characteristics are shown in Table 2.
      Antiviral therapy and/or hydroxychloroquine were employed in 28 of 37 (76%) patients for a median duration of 4 days (IQR, 3–8). Antibiotics were employed in 25 of 37 (68%): macrolides in 56%, cephalosporins in 48%, carbapenems in 8%, glycopeptides in 8%, aminoglycosides in 8%, beta-lactams in 4%, and fluoroquinolones in 4%. A total of 4 of 37 (11%) received prophylactic heparin, and 3 of 37 (8%) were on angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists.
      One patient had to withdraw from taking hydroxychloroquine due to vomiting. No other adverse event due to the treatment was documented in this patient group.
      During follow-up, 7 of 37 (19%) patients experienced a new onset/worsening of the interstitial pneumonia, 3 of 37 (8%) died, 2 of 37 (5%) developed acute respiratory distress syndrome (ARDS), and 2 of 37 (5%) had to be hospitalized. In addition, 5 of 37 patients (14%) developed cough, 5 of 37 (14%) myalgia, 4 of 37 (11%) fever, and 3 of 37 (8%) gastrointestinal symptoms during follow up.
      Patients who were asymptomatic at baseline, compared to the symptomatic ones, were less likely to develop ARDS (0 of 18 vs. 2 of 19), develop a new onset or worsening of pneumonia (1 of 18 vs. 6 of 19), and to die (0 of 18 vs. 3 of 19).

       Hospitalized patients

      Fifty-seven patients were admitted after a median time from symptom onset and from positive RT-PCR test results of 4 (IQR, 1–7) and 2 days (IQR, 1–3), respectively. Median follow-up was 8 days (IQR, 4.8–15). Detailed characteristics of this population are shown in Table 2. Antiviral therapy was employed in 45 of 57 (79%), with 13 of 45 patients (29%) experiencing adverse events: 7 diarrhea, 4 an increase in liver enzymes, 3 prolongation of QTc interval, 2 atrial fibrillation, 1 gastrointestinal bleeding, 1 coagulation alterations, and 1 skin rash. The median duration of lopinavir/ritonavir or darunavir + ritonavir and hydroxychloroquine treatments were 7 days (IQR, 5–12) and 5 days (IQR, 3–7), respectively. Antibiotics were administered in 55 of 57 patients: macrolides in 40%, cephalosporins in 49%, carbapenems in 15%, glycopeptides in 20%, aminoglycosides in 7%, beta-lactams in 25%, and fluoroquinolones in 24%. Thirty-one of 57 (54%) received prophylactic heparin, and 11 of 57 (19%) were on angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists.
      Forty-five of 57 patients (79%) developed ARDS; 24 of 57 (42%) died after a median of 6 days (IQR, 3.8–9.5) from admission and a median of 9 days (IQR, 7–10) from onset of symptoms. Eleven of 57 (19%) patients were discharged after a median of 8 days (IQR, 6.5–13) from admission and 15 days (IQR, 12.5–17.5) from onset of symptoms. Among the patients who died, the cause of death was respiratory failure secondary to ARDS in 15 of 24 (63%), bacterial sepsis in 4 of 9, and sudden death of unknown origin in 5 of 9. Serial chest X-rays were performed in 27 of 57 (47%) patients; among those patients, 20 of 27 (74%) showed chest X-ray worsening compared to baseline.
      Dexamethasone was administered to 18 of 57 (32%) patients due to respiratory deterioration; 2 of 18 of these patients also received tocilizumab. In this group, 5 of 18 patients (28%) died. Of 9 patients whose response to glucocorticoids was assessable at the moment of data analyses, 2 of 9 showed stabilization of the arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FIO2 ratio) or chest X-ray improvement, whereas the remaining patients did not improve. Regarding the 2 tocilizumab-treated patients, response was assessable in only one, with no improvements in chest X-ray or PaO2/FIO2.

       Factors associated with risk of ARDS and death

      In univariate analyses, cardiac failure (odds ratio [OR], 6.22 [95% confidence interval {CI}, 1.85–28.6]; P = 0.007), ischemic heart disease (OR, 5.61 [95% CI, 1.65–25.9]; P = 0.01), fever at disease diagnosis (OR, 18.2 [95% CI, 5.6–82.44]; P = 0.000013), shortness of breath at disease diagnosis (OR, 18.17 [95% CI, 4.8–119.5]; P = 0.0002), myalgia or fatigue at disease diagnosis (OR, 5.6 [95% CI, 1.65–25.9]; P = 0.01), infiltrates at the baseline chest X-ray (OR, 4.4 [95% CI, 1.67–13]; P = 0.004), higher aspartate aminotransferase levels (OR, 2.81 [95% CI, 1.08–7.6]; P = 0.04), and higher C-reactive protein levels (OR, 4.68 [95% CI, 1.83–12.7]; P = 0.002) were associated with the risk of developing ARDS. Ischemic heart disease (OR, 3.11 [95% CI, 1.02–9.6]; P = 0.05), fever at disease diagnosis (OR, 18.7 [95% CI, 3.62–343]; P = 0.005), cough at disease diagnosis (OR, 3.5 [95% CI, 1.28–9.7]; P = 0.01), shortness of breath at disease diagnosis (OR, 5.3 [95% CI, 2–15]; P = 0.001), and higher C-reactive protein level at disease diagnosis (OR 6, [95% CI, 2.1–19]; P = 0.001) were associated with the risk of death (Table 3).
      Table 3Univariate analyses of the association between clinical characteristics and the risk of ARDS or death in hemodialysis patients with SARS-CoV-2 infection
      VariableOutcome: ARDSOutcome: death
      OR (95% CI)P valueOR (95% CI)P value
      Sex0.68 (0.29–1.61)0.391.05 (0.41–2.78)0.93
      History of hypertension0.37 (0.05–1.83)0.250.27 (0.05–1.31)0.1
      History of cardiac failure6.22 (1.85–28.6)0.0071.04 (0.3–3.2)0.94
      History of diabetes1.7 (0.75–3.9)0.211.7 (0.69–4.2)0.25
      History of peripheral vascular disease1.27 (0.49–3.36)0.630.91 (0.29–2.56)0.86
      History of ischemic cardiac disease5.61 (1.65–25.9)0.013.11 (1.02–9.6)0.05
      History of COPD1 (0.26–3.84)11.07 (0.22–4.2)0.92
      History of cancer1.88 (0.53–7.64)0.341.5 (0.36–5.4)0.55
      Type dialysis (HDF vs. HD)0.43 (0.16–1.14)0.0971.12 (0.38–3.05)0.83
      Age (>70 yr vs. ≤70 yr)2.18 (0.96–5)0.0651.85 (0.75–4.78)0.18
      Fever at disease diagnosis18.2 (5.6–82.4)0.00001318.7 (3.62–123)0.005
      Cough at disease diagnosis1.61 (0.62–4.37)0.333.5 (1.28–9.7)0.01
      Shortness of breath at disease diagnosis18.17 (4.8–119.5)0.00025.3 (2–15)0.001
      Myalgia or fatigue at disease diagnosis5.6 (1.65–25.9)0.012.26 (0.72–6.9)0.15
      Infiltrates at chest X-ray at disease diagnosis4.4 (1.67–13)0.0042.9 (0.95–11)0.08
      WBC (≤5 ×103/ul vs. >5 ×103/ul)1.2 (0.52–1.8)0.661.82 (0.73–4.6)0.2
      Lymphocytes (≤0.75 ×103/ul vs. >0.75 ×103/ul)1.76 (0.75–4.2)0.191.5 (0.59–3.9)0.4
      Platelets (≤150 ×103/ul vs. >150 ×103/ul)1.43 (0.62–3.37)0.411.9 (0.75–4.8)0.17
      LDH (>250 U/l vs. ≤250 U/l)0.99 (0.32–3.11)0.990.71 (0.18–2.7)0.62
      AST (>25 U/l vs. ≤25 U/l)2.81 (1.08–7.6)0.041.85 (0.66–5.3)0.24
      ALT (>20 U/l vs. ≤20 U/l)1.73 (0.67–4.69)0.252.5 (0.88–7)0.085
      CRP (>50 mg/l vs. ≤50 mg/l)4.68 (1.83–12.7)0.0026 (2.1–19)0.001
      Antiviral therapy1.29 (0.48–3.55)0.620.39 (0.14–1.11)0.08
      Time from symptoms to antiviral commencement (≤5 vs. >5)2.09 (0.65–7.51)0.230.55 (0.11–2.1)0.41
      Hydroxychloroquine1.16 (0.44–3.12)0.760.44 (0.16–1.24)0.12
      Bold data refer to statistically significant P values.
      ALT, alanine aminotransferase; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; CI, confidence interval; COPD, chronic obstructive pulmonary disorder; CRP, C-reactive protein; HD, hemodialysis; HDF, hemodiafiltration; LDH, lactate dehydrogenase; OR, odds ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WBC, white blood cell.
      Two multivariate analyses were performed, one for each outcome of interest (ARDS and death). In the first model, the characteristics found to be associated with the risk of ARDS were history of ischemic heart disease (OR, 7.5 [95% CI, 1.6–36.2]; P = 0.04), fever at disease diagnosis (OR, 17 [95% CI, 4.5–64]; P = 0.0009), age at symptom onset (OR, 1.1 [95% CI, 1–1.15]; P = 0.03), and shortness of breath at disease onset (OR, 20 [95% CI, 3.6–79.3]; P = 0.004). In the second model, the characteristics associated with the risk of death were fever at disease diagnosis (OR, 18.7 [95% CI, 2.4–146]; P = 0.02), cough at disease diagnosis (OR, 4 [95% CI, 1.02–17.6]; P = 0.05), and higher serum C-reactive protein at disease diagnosis (OR, 5.6 [95% CI, 1.6–23.5]; P = 0.01; Table 4).
      Table 4Two models of multivariate analyses of the association between clinical characteristics and the risk of ARDS or death in hemodialysis patients with SARS-CoV-2 infection
      VariableOutcome: ARDS
      OR (95% CI)P value
      Model 1
       History of ischemic cardiac disease7.5 (1.6–36.3)0.04
       Fever at disease onset17 (4.5–64)0.0009
       Age at symptoms (>70 yr vs. ≤70 yr)1.1 (1–1.15)0.03
       Shortness of breath20 (3.6–79.3)0.004
       Myalgia or fatigue8.5 (0.83–40.3)0.11
      VariableOutcome: death
      OR (95% CI)P value
      Model 2
       History of ischemic cardiac disease5 (0.94–32.3)0.07
       Fever at disease onset18.7 (2.4–146)0.02
       Cough at disease onset4 (1.02–17.6)0.05
       CRP at baseline (>50 mg/l vs. ≤50 mg/l)5.6 (1.6–23.5)0.01
      Bold data refer to statistically significant P values.
      ARDS, acute respiratory distress syndrome; CI, confidence interval; CRP, C-reactive protein; OR, odds ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

       Discussion

      SARS-CoV-2 infection is challenging healthcare systems around the world. The predictions regarding COVID-19–associated mortality are changing as new information is gathered, although comorbidities such as cardiovascular diseases, diabetes, chronic respiratory diseases, hypertension, and cancer are consistently associated with worse prognoses.
      The Novel Coronavirus Pneumoniae Emergency Response Epidemiology Team
      The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Disease (COVID-19)—China.
      2020
      ,
      • Huang C.
      • Wang Y.
      • Li X.
      • et al.
      Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
      Lancet. 2020; 395: 497-506
      We have reported recently
      • Alberici F.
      • Delbarba E.
      • Manenti C.
      • et al.
      A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia.
      Kidney Int. 2020; 5: 1083-1088
      that hospitalized kidney transplant recipients tended to have a poor prognosis, with a mortality rate of 25%, and another group observed that when such patients did not require hospital admission, they experienced a more favorable outcome.
      • Banerjee D.
      • Popoola J.
      • Shah S.
      • et al.
      COVID-19 infection in kidney transplant recipients.
      Kidney Int. 2020; 5: 1076-1082
      The prognosis of hemodialysis patients with COVID-19 is still unclear, and more data are desperately needed. In our cohort, including 4 centers that are part of the Brescia Renal COVID Task Force, we have identified 94 patients with SARS-CoV-2 infection. As expected, infected MHD patients who do not require hospital admission experienced a better disease course compared to patients who required hospitalization. Nevertheless, 5% of the patients treated in the outpatient setting subsequently required admission. There was also substantially less use of antiviral medications in patients managed in the outpatient setting, although the proportion of patients receiving hydroxychloroquine was similar between the 2 groups. These findings should be taken into account when interpreting the results, as it was the managing physician’s decision to start medications. Although the lower rate of antiviral use was associated with a lower incidence of adverse events in the outpatient group, whether this may be the result of less-frequent antiviral use rather than a better overall disease profile needs to be clarified. Finally, in our cohort, only a few patients were treated with glucocorticoids and tocilizumab, which does not allow us to draw any conclusions on the potential efficacy of these treatments.
      The disease severity of the SARS-CoV-2 infection is highly variable, and a significant proportion of infected patients appear to experience only mild disease or no symptoms at all in our cohort. Notably, the overall case fatality rate of our population was higher compared to that in the general Italian and Chinese population (28% vs. 7.2% vs. 2.3%).
      • Wu Z.
      • McGoogan J.M.
      Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention.
      JAMA. 2020; 323: 1239-1242
      ,

      Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy [e-pub ahead of print]. JAMA. https://doi.org/10.1001/jama.2020.4683. Accessed April 14, 2020.

      The finding of worse outcome of hemodialysis patients with SARS-CoV-2 infection may be explained by a high prevalence of comorbidities, as well as other risk factors related to end-stage renal disease per se.

      Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection [e-pub ahead of print]. Int Urol Nephrol. https://doi.org/10.1007/s11255-020-02451-9. Accessed April 13, 2020.

      Our study also provides some preliminary information on factors associated with the risk of ARDS and death. The presence of cardiovascular disease and severe inflammation were predictive of worse outcomes. Notably, these factors are not specific for the hemodialysis population, as cardiac comorbidities, fever, and older age have already been described as prognostic factors in the general population with SARS-CoV-2 infection.

      Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China [e-pub ahead of print]. JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2020.0994. Accessed April 14, 2020.

      ,
      • Yang X.
      • Yu Y.
      • Xu J.
      • et al.
      Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
      Lancet Respir Med. 2020; 8: 475-481
      Our results should be interpreted with some caution. The median follow-up period was 8 days; center bias cannot be ruled out; symptoms severity was not collected; and the relatively small sample size of our cohort may have had an impact on the generalizability of our analyses. The strengths of our study include a shared management approach characterized by relative data homogeneity, and detailed data collection made possible by an unprecedented commitment of the members of our task force.
      In conclusion, SARS-CoV-2 infection in maintenance hemodialysis patients presents with a wide range of symptoms. The data represented herein suggest a strikingly higher mortality rate compared to that in the general population, although the risk factors for disease severity are similar. Further data collection and follow-up are necessary to gain a complete picture of the spectrum of COVID-19 in maintenance dialysis patients.

       Methods

      From March 1, 2020 to April 3, 2020, we enrolled all hemodialysis patients with SARS-CoV-2 infection who were managed within 4 hemodialysis hubs (Table 1) of the Brescia Renal COVID Task Force. Each one of these dialysis centers implemented general prevention measures to safeguard their population. Three of the 4 hemodialysis hubs reserved the RT-PCR test for only those patients showing symptoms suggestive of the disease, after their referral to dedicated clinics. Conversely, starting on March 20th, the Brescia dialysis unit performed RT-PCR analysis on all patients followed.
      The therapeutic strategy followed our protocol.
      • Alberici F.
      • Delbarba E.
      • Manenti C.
      • et al.
      Management of patients on dialysis and with kidney transplantation during the SARS-CoV-2 (COVID-19) pandemic in Brescia, Italy.
      Kidney Int Rep. 2020; 5: 580-585
      Antiviral therapy based on lopinavir/ritonavir associated to hydroxychloroquine (with dose adjusted according to kidney function) was considered for all patients, if not contraindicated. In cases of shortage of lopinavir/ritonavir, darunavir and ritonavir were employed. Patients experiencing clinical deterioration after at least 7 days following symptom onset, or no fever for >72 hours, with escalating oxygen requirements, progression of the chest X-ray, and no signs of bacterial infection, were considered for dexamethasone (20 mg/d for 5 days, then 10 mg/d for 5 days) and up to 2 tocilizumab infusions at an interval of 12–24 hours (8 mg/kg of body weight, maximum dose per infusion 800 mg).
      Considering the well-known potential of lopinavir/ritonavir and hydroxychloroquine for increasing QTc, a baseline EKG was performed before therapy commencement and afterwards, every 2–3 days; in case of QTc prolongation, a reduction or discontinuation of treatment was considered in a case-by-case manner.
      ARDS and cardiac failure have been defined as reported by others.
      • Force A.D.T.
      • Ranieri V.M.
      • Rubenfeld G.D.
      • et al.
      Acute respiratory distress syndrome: the Berlin Definition.
      JAMA. 2012; 307: 2526-2533
      ,
      • Yancy C.W.
      • Jessup M.
      • Bozkurt B.
      • et al.
      2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
      J Am Coll Cardiol. 2013; 62: e147-e239
      The decision as to whether to admit a patient was made by the attending physician according to symptom severity or signs of respiratory failure.
      Ethical approval for this study was obtained according to Italian regulations.

       Statistical analyses

      Statistical analysis was performed using R software (https://www.r-project.org) and GraphPad Prism 7. Results are expressed as the number and percentage for categorical variables, and the median (IQR) for continuous variables.
      Changes in variables were compared by a related sample Wilcoxon test; proportions of patients were compared using a χ2 or Fisher test, as appropriate.
      Univariate and multiple logistic regression models were used to assess the ability of some predefined clinical characteristics to predict the risk of ARDS or death. All the statistically significant predictors at univariate analysis were entered in a multivariate model.
      • McMichael T.M.
      • Currie D.W.
      • Clark S.
      • et al.
      Epidemiology of Covid-19 in a long-term care facility in King County, Washington.
      N Engl J Med. 2020; 382: 2005-2011
      Finally, the best multivariate model was identified by adopting a stepwise selection approach. ORs and their 95% CIs were estimated from logistic regression analysis. P values less than 0.05 (2-tailed) were considered significant.

      Disclosure

      All the authors declared no competing interests.

      References

        • Alberici F.
        • Delbarba E.
        • Manenti C.
        • et al.
        Management of patients on dialysis and with kidney transplantation during the SARS-CoV-2 (COVID-19) pandemic in Brescia, Italy.
        Kidney Int Rep. 2020; 5: 580-585
        View in Article

      2. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection [e-pub ahead of print]. Int Urol Nephrol. https://doi.org/10.1007/s11255-020-02451-9. Accessed April 13, 2020.

        View in Article

      3. Wang R, Liao C, He H, et al. COVID-19 in hemodialysis patients: a report of 5 cases [e-pub ahead of print]. Am J Kidney Dis. https://doi.org/10.1053/j.ajkd.2020.03.009. Accessed April 12, 2020.

        View in Article
        • Burgner A.
        • Ikizler T.A.
        • Dwyer J.P.
        COVID-19 and the inpatient dialysis unit: managing resources during contingency planning pre-crisis.
        Clin J Am Soc Nephrol. 2020; 15: 720-722
        View in Article
        • The Novel Coronavirus Pneumoniae Emergency Response Epidemiology Team
        The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Disease (COVID-19)—China.
        2020 ([press release]. Available at: http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51. Accessed March 22, 2020)
        View in Article
        • Huang C.
        • Wang Y.
        • Li X.
        • et al.
        Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
        Lancet. 2020; 395: 497-506
        View in Article
        • Alberici F.
        • Delbarba E.
        • Manenti C.
        • et al.
        A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia.
        Kidney Int. 2020; 5: 1083-1088
        View in Article
        • Banerjee D.
        • Popoola J.
        • Shah S.
        • et al.
        COVID-19 infection in kidney transplant recipients.
        Kidney Int. 2020; 5: 1076-1082
        View in Article
        • Wu Z.
        • McGoogan J.M.
        Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention.
        JAMA. 2020; 323: 1239-1242
        View in Article

      10. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy [e-pub ahead of print]. JAMA. https://doi.org/10.1001/jama.2020.4683. Accessed April 14, 2020.

        View in Article

      11. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China [e-pub ahead of print]. JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2020.0994. Accessed April 14, 2020.

        View in Article
        • Yang X.
        • Yu Y.
        • Xu J.
        • et al.
        Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
        Lancet Respir Med. 2020; 8: 475-481
        View in Article
        • Force A.D.T.
        • Ranieri V.M.
        • Rubenfeld G.D.
        • et al.
        Acute respiratory distress syndrome: the Berlin Definition.
        JAMA. 2012; 307: 2526-2533
        View in Article
        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • et al.
        2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2013; 62: e147-e239
        View in Article
        • McMichael T.M.
        • Currie D.W.
        • Clark S.
        • et al.
        Epidemiology of Covid-19 in a long-term care facility in King County, Washington.
        N Engl J Med. 2020; 382: 2005-2011
        View in Article

      Article Info

      Publication History

      Published online: May 10, 2020
      Accepted: April 29, 2020
      Received in revised form: April 24, 2020
      Received: April 15, 2020

      Identification

      DOI: https://doi.org/10.1016/j.kint.2020.04.030

      Copyright

      © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      Linked Article

      • De-isolation of COVID-19–positive hemodialysis patients in the outpatient setting: a single-center experience
        Kidney InternationalVol. 98Issue 1
        • Preview
          The advice for patients presenting with coronavirus disease 2019 (COVID-19) symptoms is to self-isolate for 7 days after the onset of symptoms for the individual case and 14 days for the household.1 Dialysis patients can be considered as immunocompromised and display a decreased ability to develop seroconversion to infectious diseases.2 Therefore, 7 to 14 days may not be an appropriate threshold in a dialysis population. In our center, we provide dialysis in 2 hospital-based and 6 satellite units, for a total of 664 patients (see Supplementary Methods).
        • Full-Text
        • PDF
      • COVID-19 in dialysis patients: adding a few more pieces to the puzzle
        Kidney InternationalVol. 98Issue 1
        • Preview
          Maintenance hemodialysis (MHD) patients are at increased risk for coronavirus disease 2019 (COVID-19) and its complications, owing to the presence of multiple comorbid conditions. The logistical aspects within a dialysis facility further increase the risk of disease transmission.1 Despite these obvious concerns, early reports from the epicenter of the disease—Wuhan, Hubei Province in China—suggested that the incidence of COVID-19 was lower than expected, with potentially a milder course and outcomes in MHD patients.
        • Full-Text
        • PDF
      • COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain
        Kidney InternationalVol. 98Issue 1
        • Preview
          Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia emerged in Wuhan, China in December 2019. Unfortunately, there is a lack of evidence about the optimal management of novel coronavirus disease 2019 (COVID-19), and even less is available in patients on maintenance hemodialysis therapy than in the general population. In this retrospective, observational, single-center study, we analyzed the clinical course and outcomes of all maintenance hemodialysis patients hospitalized with COVID-19 from March 12th to April 10th, 2020 as confirmed by real-time polymerase chain reaction.
        • Full-Text
        • PDF
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2021 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX